Evenamide

Last updated

Evenamide
Evenamide.svg
Clinical data
Other namesNW-3509; NW-3509A
Routes of
administration 		oral
ATC code
  • None
Identifiers
  • 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C16H26N2O2
Molar mass 278.396 g·mol−1
3D model (JSmol)
  • CCCCOc1cccc(CCNCC(=O)N(C)C)c1
  • InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
  • Key:GRHBODILPPXVKN-UHFFFAOYSA-N

Evenamide (INN Tooltip International Nonproprietary Name) (developmental code names NW-3509, NW-3509A) [1] is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. [2] [3] [4] [5] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. [4] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015. [6]

Contents

The drug was discovered by Newron Pharmaceuticals SpA, a pharmaceutical company located in Italy [7] and according to the company, it shows benefit to the management of schizophrenia to poorly responded treatment with antipsychotics. It acts exclusively through glutamatergic inhibition.

Clinical studies

In a randomized study with treatment-resistant schizophrenia patients, evenamide was added to the treatment regimen, with the psychological assessors being blinded to whether evenamide was taken. 70% of the participants reported a significant lowering of their impairments; and in 25%, schizophrenia went in full remission. A full double-blind phase III study with treatment-resistant schizophrenia patients is in preparation as of January 2023. [8]

The 4 week placebo trial of 2021 to evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide for people with chronic schizophrenia was selected to address patients who are receiving treatment at constant doses of one of the following atypical antipsychotics: aripiprazole, clozapine, quetiapine, olanzapine, paliperidone or risperidone. [9] [10]

See also

Related Research Articles

<span class="mw-page-title-main">Antipsychotic</span> Class of medications

Antipsychotics, previously known as neuroleptics and major tranquilizers, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia but also in a range of other psychotic disorders. They are also the mainstay, together with mood stabilizers, in the treatment of bipolar disorder. Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder.

<span class="mw-page-title-main">Risperidone</span> Antipsychotic medication

Risperidone, sold under the brand name Risperdal among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder, as well as irritability associated with autism. It is taken either by mouth or by injection. The injectable versions are long-acting and last for 2–4 weeks.

<span class="mw-page-title-main">Olanzapine</span> Atypical antipsychotic medication

Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. It is also sometimes used off-label for treatment of chemotherapy-induced nausea and vomiting and as an appetite stimulant. For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is taken by mouth or by injection into a muscle.

<span class="mw-page-title-main">Lamotrigine</span> Medication used for bipolar disorder, epilepsy, & many seizure disorders

Lamotrigine, sold under the brand name Lamictal among others, is a medication used to treat epilepsy and stabilize mood in bipolar disorder. For epilepsy, this includes focal seizures, tonic-clonic seizures, and seizures in Lennox-Gastaut syndrome. In bipolar disorder, lamotrigine has not been shown to reliably treat acute depression in any groups except for the severely depressed; but for patients with bipolar disorder who are not currently symptomatic, it appears to reduce the risk of future episodes of depression.

<span class="mw-page-title-main">Amisulpride</span> Atypical antipsychotic and antiemetic medication

Amisulpride, sold under the brand names Solian and Barhemsys, is a medication used in the treatment of schizophrenia, acute psychotic episodes, depression, and nausea and vomiting. It is specifically used at lower doses intravenously to prevent and treat postoperative nausea and vomiting; at low doses by mouth to treat depression; and at higher doses by mouth to treat psychosis.

<span class="mw-page-title-main">Melperone</span> Antipsychotic drug

Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. It first entered clinical use in 1960s.

<span class="mw-page-title-main">Safinamide</span> Reversible monoamine oxidase B inhibitor

Safinamide, sold under the brand name Xadago, is a medication used as treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.

<span class="mw-page-title-main">Pimavanserin</span> Atypical antipsychotic medication

Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist, but rather is a selective inverse agonist of the serotonin 5-HT2A receptor.

<span class="mw-page-title-main">Pomaglumetad</span> Drug, used as a treatment for schizophrenia

Pomaglumetad (LY-404,039) is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3. Pharmacological research has focused on its potential antipsychotic and anxiolytic effects. Pomaglumetad is intended as a treatment for schizophrenia and other psychotic and anxiety disorders by modulating glutamatergic activity and reducing presynaptic release of glutamate at synapses in limbic and forebrain areas relevant to these disorders. Human studies investigating therapeutic use of pomaglumetad have focused on the prodrug LY-2140023, a methionine amide of pomaglumetad (also called pomaglumetad methionil) since pomaglumetad exhibits low oral absorption and bioavailability in humans.

<span class="mw-page-title-main">Funapide</span> Analgesic drug under development

Funapide (INN) is a novel analgesic under development by Xenon Pharmaceuticals for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain. It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker. Funapide is being evaluated in humans in both oral and topical formulations, and as of July 2014, has reached phase IIb clinical trials.

<span class="mw-page-title-main">Vixotrigine</span> Analgesic drug under development

Vixotrigine, formerly known as raxatrigine, is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker. Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain. It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.

<span class="mw-page-title-main">DSP-2230</span> Investigational analgesic drug

DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain. As of June 2014, it is in phase I/phase II clinical trials.

<span class="mw-page-title-main">AVN-211</span> Chemical compound

AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia. In early 2011, it successfully completed phase IIa clinical trials, with benefits on positive symptoms and some procognitive effects observed, and in mid 2013, phase IIb clinical trials for schizophrenia began. Avineuro Pharmaceuticals also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease in 2015.

<span class="mw-page-title-main">Ralfinamide</span> Investigational analgesic drug

Ralfinamide (INN) is a multimodal drug which is under investigation by Newron Pharmaceuticals for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain.

<span class="mw-page-title-main">Brilaroxazine</span> Experimental atypical antipsycotic

Brilaroxazine, also known as oxaripiprazole, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of neuropsychiatric and inflammatory disorders. It has currently completed the first of two phase III clinical trials for schizophrenia. Reviva Pharmaceuticals also intends to investigate brilaroxazine for the treatment of bipolar disorder, major depressive disorder, attention deficit hyperactivity disorder (ADHD), irritability in autism, tics, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, as well as the inflammatory disorders pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), and psoriasis. The FDA granted brilaroxazine orphan drug designation for the treatment of PAH and IPF.

<span class="mw-page-title-main">Neboglamine</span> Chemical compound

Neboglamine, formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence. It shows cognition- and memory-enhancing effects in animal models. As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.

<span class="mw-page-title-main">Ralmitaront</span> Investigational antipsychotic drug

Ralmitaront is an investigational antipsychotic drug which is undergoing a clinical trial for the treatment of negative symptoms in schizophrenia and schizoaffective disorder. Another clinical trial targeting acute psychotic symptoms of schizophrenia has been terminated due to lack of efficacy. It is a partial agonist of the TAAR1. The medication is being developed by the pharmaceutical company Hoffmann-La Roche. Ralmitaront had completed phase 1 clinical trials.

<span class="mw-page-title-main">Xanomeline/trospium chloride</span> Medication

Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. It contains xanomeline, a muscarinic agonist; and trospium chloride, a muscarinic antagonist. Xanomeline is a functionally preferring muscarinic M4 and M1 receptor agonist. Trospium chloride is a non-selective muscarinic antagonist.

References

  1. ↑ Singh R, Hahn MK, Bansal Y, Agarwal SM, Remington G (February 2024). "Evenamide: A Potential Pharmacotherapeutic Alternative for Treatment-Resistant Schizophrenia". The International Journal of Neuropsychopharmacology. 27 (2): pyae005. doi:10.1093/ijnp/pyae005. PMC   10858345 . PMID   38195245.
  2. ↑ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN   1178-2595. S2CID   8513976.
  3. ↑ Kemp MI (2010). "Structural trends among second-generation voltage-gated sodium channel blockers". Progress in Medicinal Chemistry. 49: 81–111. doi:10.1016/S0079-6468(10)49003-7. ISBN   978-0-12-381292-6. PMID   20855039.
  4. 1 2 Zuliani V, Amori L, Rivara M (21 June 2011). "Advances in Design of Development of Sodium Channel Blockers". In Gupta SP (ed.). Ion Channels and Their Inhibitors. Springer Science & Business Media. pp. 102–. ISBN   978-3-642-19922-6.
  5. ↑ Zuliani V, Amori L, Rivara M (2011). "Advances in Design and Development of Sodium Channel Blockers". Ion Channels and Their Inhibitors. pp. 79–115. doi:10.1007/978-3-642-19922-6_4. ISBN   978-3-642-19921-9.
  6. ↑ "Newron raised new funds to continue the development of Neurological therapies". Labiotech. 5 February 2015. Archived from the original on 4 March 2016.
  7. ↑ "Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients". Newron Pharmaceuticals. Retrieved 2024-06-28.
  8. ↑ "Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)". Newron Pharmaceuticals. 2024-01-04. Retrieved 2024-01-04.
  9. ↑ "ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2024-06-28.
  10. ↑ "Evenamide: New Positive Results From Study 008A". Psychiatric Times. 2024-04-30. Retrieved 2024-06-28.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.